Evidence map›Paper›PMID 38659832›Full record

ArticlebioRxiv : the preprint server for biology2024

Cross-reactivity of r

Saidou Balam, Kazutoyo Miura, Imen Ayadi, Drissa Konaté, Nathan C Incandela, Valentina Agnolon, Merepen A Guindo, Seidina A S Diakité, Sope Olugbile, Issa Nebie and 7 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 6 countries.

Saidou BalamInternational Center for Excellence in Research (ICER-Mali), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.ORCID 0000-0002-7178-7758
Kazutoyo MiuraLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.ORCID 0000-0003-4455-2432
Imen AyadiImmunobiology Department, University of Lausanne, Lausanne, Switzerland.
Drissa KonatéInternational Center for Excellence in Research (ICER-Mali), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Nathan C IncandelaImmunobiology Department, University of Lausanne, Lausanne, Switzerland.
Valentina AgnolonDivision of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland aaaa.
Merepen A GuindoInternational Center for Excellence in Research (ICER-Mali), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Seidina A S DiakitéInternational Center for Excellence in Research (ICER-Mali), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Sope OlugbileImmunobiology Department, University of Lausanne, Lausanne, Switzerland.
Issa NebieGroupe de Recherche Action Santé (GRAS), Burkina Faso, West Africa.
Sonia M HerreraCaucaseco Scientific Research Center, Cali, Colombia.
Carole LongLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Andrey V KajavaMontpellier Cell Biology Research Center (CRBM), University of Montpellier, CNRS, France.ORCID 0000-0002-2342-6886
Mahamadou DiakitéInternational Center for Excellence in Research (ICER-Mali), University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Giampietro CorradinImmunobiology Department, University of Lausanne, Lausanne, Switzerland.
Socrates HerreraCaucaseco Scientific Research Center, Cali, Colombia.
Myriam Arevalo HerreraMalaria Vaccine and Drug Development Center, Cali, Colombia.ORCID 0000-0002-3434-9425
Université des Sciences, des Techniques et des Technologies de Bamako · MLUniversity of Lausanne · CHCaucaseco Scientific Research Center · CONational Institutes of Health · USCentre National de la Recherche Scientifique · FRGroupe de Recherche et d’Action sur le Foncier · BFUniversity Hospital of Lausanne · CH

Funding

Plasmodium vivax 48/45 gametocyte protein: functional characterization and vaccine potential assessment in preclinical studiesR01AI121237 · NIAID · MALARIA VACCINE DEVELOPMENT CENTER · PI AREVALO-HERRERA, MYRIAM · 2016 to 2019
$1.6M
NIAID NIH HHS R01 AI121237
6 · The paper itself

Abstract

Background: Methods: r Results: r Conclusion: African sera (exposed only to

Indexed as

Cross-reactive antibodiesP. falciparum African serarPvs48/45 proteinTransmission-blocking vaccine

Identifiers

PMID38659832
PMCPMC11042229
OpenAlexW4394821466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.